Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C

T.J. Price; D. Zannino; K. Wilson; R.J. Simes; J. Cassidy; Guy Van Hazel; B.A. Robinson; A. Broad; V. Ganju; S.P. Ackland; N.C. Tebbutt

doi:10.1093/annonc/mdr488

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C

T.J. Price, D. Zannino, K. Wilson, R.J. Simes, J. Cassidy, Guy Van Hazel, B.A. Robinson, A. Broad, V. Ganju, S.P. Ackland, N.C. Tebbutt

Research output: Contribution to journal › Article › peer-review

112 Citations (Scopus)

Original language	English
Pages (from-to)	1531-1536
Journal	Annals of Oncology
Volume	23
DOIs	https://doi.org/10.1093/annonc/mdr488
Publication status	Published - 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/annonc/mdr488

Cite this

Price, T. J., Zannino, D., Wilson, K., Simes, R. J., Cassidy, J., Van Hazel, G., Robinson, B. A., Broad, A., Ganju, V., Ackland, S. P., & Tebbutt, N. C. (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Annals of Oncology, 23, 1531-1536. https://doi.org/10.1093/annonc/mdr488

@article{475d9f4506394ee982868c8be3668146,

title = "Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C",

author = "T.J. Price and D. Zannino and K. Wilson and R.J. Simes and J. Cassidy and {Van Hazel}, Guy and B.A. Robinson and A. Broad and V. Ganju and S.P. Ackland and N.C. Tebbutt",

year = "2012",

doi = "10.1093/annonc/mdr488",

language = "English",

volume = "23",

pages = "1531--1536",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

Price, TJ, Zannino, D, Wilson, K, Simes, RJ, Cassidy, J, Van Hazel, G, Robinson, BA, Broad, A, Ganju, V, Ackland, SP & Tebbutt, NC 2012, 'Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C', Annals of Oncology, vol. 23, pp. 1531-1536. https://doi.org/10.1093/annonc/mdr488

Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. / Price, T.J.; Zannino, D.; Wilson, K. et al.
In: Annals of Oncology, Vol. 23, 2012, p. 1531-1536.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C

AU - Price, T.J.

AU - Zannino, D.

AU - Wilson, K.

AU - Simes, R.J.

AU - Cassidy, J.

AU - Van Hazel, Guy

AU - Robinson, B.A.

AU - Broad, A.

AU - Ganju, V.

AU - Ackland, S.P.

AU - Tebbutt, N.C.

PY - 2012

Y1 - 2012

U2 - 10.1093/annonc/mdr488

DO - 10.1093/annonc/mdr488

M3 - Article

SN - 0923-7534

VL - 23

SP - 1531

EP - 1536

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Price TJ, Zannino D, Wilson K, Simes RJ, Cassidy J, Van Hazel G et al. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C. Annals of Oncology. 2012;23:1531-1536. doi: 10.1093/annonc/mdr488